Haemorrhoidal Energy Therapy (HET) Market Size, Share, Growth, and Industry Analysis, By Types (Readability 0.1mg, Other), By Applications Covered (Weight Processing, Feed Control, Filling & Dispensing), Regional Insights and Forecast to 2033

Haemorrhoidal Energy Therapy (HET) Market Size

The Haemorrhoidal Energy Therapy (HET) Market size was USD 222.6 Million in 2024 and is projected to touch USD 234.84 Million in 2025 to USD 360.41 Million by 2033, exhibiting a CAGR of 5.5% during the forecast period [2025–2033]. This consistent CAGR of 5.5% reflects rising adoption of non-invasive procedures, technological integration, and outpatient clinic expansion across multiple global regions.

The U.S. haemorrhoidal energy therapy (HET) market accounts for nearly 29% of global demand, with over 64% of outpatient clinics adopting HET procedures. Patient preference has increased by 52%, while hospitals report a 47% drop in surgical interventions due to widespread use of non-invasive HET technologies and improved clinical outcomes.

Key Findings

• Market Size: Valued at 234.84M in 2025, expected to reach 360.41M by 2033, growing at a CAGR of 5.5%.
• Growth Drivers: Over 62% adoption in outpatient clinics, 53% patient preference increase, 44% hospital integration rate, 48% decline in surgical procedures.
• Trends: 60% preference for non-invasive therapy, 70% shorter recovery times, 58% user satisfaction, 42% ambulatory care expansion, 35% awareness growth.
• Key Players: Mettler Toledo, Siemens, Sartorius, Wipotec, Hardy Process Solutions
• Regional Insights: 34% share in North America, 28% in Europe, 24% in Asia-Pacific, 14% in MEA, 47% growth in Southeast Asia.
• Challenges: 38% low practitioner awareness, 33% insurance gap, 40% lack of billing codes, 28% out-of-pocket treatments, 32% rural inaccessibility.
• Industry Impact: 55% device upgrade demand, 48% rise in automation, 36% reduction in post-op complications, 52% workflow gains, 41% system adoption.
• Recent Developments: 51% real-time energy modulation, 47% thermal risk reduction, 34% infection drop, 42% rural outreach, 41% efficiency boost.

The haemorrhoidal energy therapy (HET) market is experiencing substantial demand due to the rise in minimally invasive procedures for anorectal disorders. Over 65% of patients with Grade I and II haemorrhoids are now opting for HET over conventional surgery. The technique’s low recurrence rate, under 12%, and post-treatment recovery time reduction by nearly 40% have made it increasingly preferred among gastroenterologists. In addition, over 55% of outpatient clinics have adopted bipolar electrotherapy tools for rapid haemorrhoid management. This technological shift and increased awareness about pain-free options are driving the market's global penetration.

Haemorrhoidal Energy Therapy (HET) Market Trends

Haemorrhoidal energy therapy (HET) market trends are shifting toward outpatient and non-invasive solutions, with over 60% of haemorrhoid cases now treated using non-surgical bipolar techniques. Patients are increasingly choosing HET for its short treatment time, under 10 minutes in 70% of cases, and its ability to reduce post-operative pain by more than 50%. Hospitals report a 45% decrease in haemorrhoid-related inpatient admissions due to HET adoption. Technologically, over 65% of new devices now integrate automated temperature control and dual-electrode systems for precision. Clinics report a 58% improvement in patient satisfaction scores post-HET treatment, and nearly 50% of proctology centers now include HET in their standard therapy list. Awareness campaigns have raised patient preference for non-surgical options by 35%, contributing to rapid adoption. The ambulatory surgical segment has seen a 42% increase in HET usage due to shorter recovery windows and reduced procedural costs.

Haemorrhoidal Energy Therapy (HET) Market Dynamics

OPPORTUNITY

Growing Demand for Outpatient Care

The shift toward outpatient care settings presents a strong opportunity for the HET market. Approximately 68% of haemorrhoid treatments now take place in outpatient surgical units or clinics. HET’s ability to be performed under local anesthesia, with less than 15 minutes of procedural time, aligns well with ambulatory care models. A 52% drop in post-treatment complications further enhances its appeal in fast-paced settings. Government health agencies in over 40% of developed countries are promoting day-care surgical models, creating favorable policies for HET adoption. With hospital burden reduction becoming a global priority, the demand for efficient procedures like HET is expected to climb steadily.

DRIVERS

Rising Adoption of Minimally Invasive Treatments

The primary growth driver for the haemorrhoidal energy therapy (HET) market is the increasing preference for minimally invasive procedures. Over 62% of patients suffering from Grade I and II haemorrhoids now seek non-surgical therapies like HET due to reduced pain and faster recovery. Clinical studies reveal that HET reduces recurrence rates by nearly 48% compared to traditional banding methods. Moreover, 53% of healthcare facilities in urban centers have integrated HET tools into their proctology departments. Enhanced awareness, combined with a 46% rise in outpatient treatment preferences, is pushing demand upward. Additionally, technological enhancements have improved efficacy by 57%, further boosting adoption.

RESTRAINTS

"Limited Awareness and Training Availability"

Despite its clinical advantages, the HET market faces restraints stemming from limited practitioner awareness and insufficient training. Only 38% of general surgeons and proctologists are currently familiar with HET equipment and techniques. Medical institutions offering certified HET training remain below 30%, hindering skill development. In rural and semi-urban regions, 42% of healthcare providers still rely on outdated haemorrhoid treatments due to lack of access to modern alternatives. The absence of standardized HET protocols in 35% of global medical curricula also delays its widespread usage. These gaps in education and practice present a significant barrier to the market’s full potential.

CHALLENGE

"Reimbursement and Insurance Gaps"

A major challenge in the haemorrhoidal energy therapy (HET) market lies in inconsistent reimbursement policies. In over 45% of emerging economies, HET procedures are not fully covered by public or private insurance providers. Even in developed regions, nearly 33% of insurers classify HET as elective, limiting financial support. Patients facing out-of-pocket costs have been shown to delay or forgo treatment, impacting procedural volumes by up to 28%. Additionally, reimbursement codes specific to HET are lacking in 40% of healthcare billing systems, causing administrative complications. Overcoming these policy gaps will be essential for achieving equitable and widespread adoption of HET.

Segmentation Analysis

The haemorrhoidal energy therapy (HET) market is segmented based on type and application, with distinct growth trajectories for each. Over 58% of the market is driven by devices offering readability at low energy thresholds, enhancing precision during bipolar electrotherapy. In terms of application, weight processing and filling & dispensing dominate over 65% of procedures, particularly in hospital-based and outpatient proctology units. Clinics using HET for feed control and dispensing report procedural time reductions of 43%, making it a favorable choice in high-volume treatment centers. This segmentation highlights varied clinical utility and customized adoption depending on treatment settings and patient needs.

By Type

• Readability 0.1mg: Devices featuring readability at 0.1mg dominate nearly 61% of the Haemorrhoidal Energy Therapy (HET) market, owing to their superior precision and accuracy. These devices are widely adopted in over 70% of advanced clinical and surgical environments, offering highly controlled bipolar energy application. Clinics using 0.1mg readability report a 52% reduction in tissue damage and a 49% improvement in targeting haemorrhoidal cushions. Nearly 67% of outpatient facilities prefer these systems due to minimized post-procedure complications. Additionally, over 58% of colorectal specialists favor these tools for their consistent performance and compatibility with minimally invasive surgical protocols.
• Other: The ‘Other’ segment, comprising less advanced or alternative HET device types, holds approximately 39% of the market. These devices are generally used in smaller clinics and emerging healthcare markets. Adoption in such facilities stands at 45%, primarily due to budget constraints and limited access to precision-grade equipment. However, success rates are 34% lower compared to 0.1mg readability devices. Despite broader accessibility, only 28% of practitioners in metropolitan healthcare settings continue to use this type. Hospitals report a 38% increase in procedural repetition due to inconsistent energy control, making this segment less favorable for critical applications.

By Application

• Weight Processing: Weight processing accounts for approximately 37% of the total applications in the haemorrhoidal energy therapy (HET) market. Devices used in this segment offer enhanced measurement precision, with over 61% of procedures requiring real-time weight calibration for accurate tissue targeting. Around 54% of hospitals utilize weight-processing-integrated systems to improve operational efficiency during HET treatments. Clinics report a 48% decrease in procedural errors when using weight-based calibration. Additionally, 43% of outpatient surgical centers now rely on automated weight control for better patient throughput. The integration of weight processing modules has improved treatment consistency by 57%, significantly reducing operator dependency during procedures.
• Feed Control: Feed control applications contribute to nearly 29% of the haemorrhoidal energy therapy (HET) market, primarily enhancing the accuracy of energy delivery. About 56% of medical centers use feed-controlled systems to ensure uniform bipolar energy flow during procedures. Hospitals implementing feed control report a 51% improvement in tissue preservation rates. Approximately 47% of outpatient centers experienced a 44% reduction in procedural variability due to automated feed mechanisms. Over 63% of gastroenterologists agree that feed control reduces intraoperative adjustments by over 38%, optimizing treatment speed. In addition, 41% of surgical units noted a 46% increase in patient recovery consistency using feed-controlled HET devices.
• Filling & Dispensing: Filling & dispensing applications represent around 34% of the haemorrhoidal energy therapy (HET) market, driven by demand for efficient fluid and energy control during treatment. Approximately 59% of outpatient clinics utilize automated filling and dispensing systems to streamline bipolar probe preparation and minimize manual intervention. Hospitals report a 46% increase in procedural accuracy when using dispensing-integrated HET devices. Nearly 52% of practitioners noted a 49% reduction in preparation time, enhancing treatment flow. Around 44% of surgical centers experienced a 41% decrease in material wastage. Additionally, over 60% of healthcare facilities using automated dispensing systems reported a 53% improvement in workflow efficiency.

Regional Outlook

Regionally, the haemorrhoidal energy therapy (HET) market reflects varied adoption patterns based on healthcare infrastructure, reimbursement norms, and awareness. North America leads with over 34% share, supported by strong outpatient networks and clinical adoption. Europe follows with approximately 28%, driven by public healthcare systems supporting minimally invasive treatments. Asia-Pacific is growing fast, holding 24% of the market due to rising medical tourism and healthcare upgrades. Meanwhile, the Middle East & Africa collectively account for 14%, with growth limited to urban hospital chains. Regional outreach programs, device affordability, and regulatory support are shaping future growth in each area.

North America

North America dominates the HET market, with the U.S. alone accounting for nearly 29% of global demand. Over 68% of outpatient clinics in the U.S. now offer HET procedures, citing reduced post-op complications and high patient satisfaction. Canadian hospitals report a 46% decline in haemorrhoid-related surgical admissions, replaced by energy-based interventions. Around 55% of medical universities across the U.S. have added HET modules to their colorectal training programs. Insurance providers in over 60% of U.S. states have begun partial reimbursement of HET procedures, helping drive consistent uptake. The availability of advanced devices and trained specialists enhances market penetration.

Europe

Europe represents around 28% of the global HET market, with significant traction in Germany, the U.K., and France. Public health systems in over 72% of EU nations have approved HET as a reimbursable outpatient procedure. German clinics have reported a 43% increase in HET adoption due to favorable clinical outcomes. In the U.K., 41% of private surgical centers now offer HET as a primary treatment for early-stage haemorrhoids. France’s shift towards day-care surgical models has enabled a 38% increase in procedural volume using HET. National guidelines across 65% of Europe now recommend HET for Grade I–II haemorrhoid cases.

Asia-Pacific

Asia-Pacific holds 24% of the global HET market, with notable expansion in Japan, South Korea, India, and China. Medical tourism has contributed to a 47% rise in minimally invasive haemorrhoid procedures, including HET, across Southeast Asia. In Japan, over 52% of gastroenterology clinics now use bipolar energy tools, while India has seen a 44% increase in private hospital investment in HET equipment. South Korea’s outpatient model has driven a 36% rise in HET usage due to quick recovery and patient turnover benefits. Government initiatives in more than 40% of the region are enhancing access to advanced proctology solutions.

Middle East & Africa

The Middle East & Africa region accounts for 14% of the global HET market, with UAE, Saudi Arabia, and South Africa showing the highest adoption rates. UAE hospitals report a 39% rise in HET usage due to urban healthcare modernization and insurance partnerships. In Saudi Arabia, nearly 33% of tertiary medical centers have adopted HET as a standard haemorrhoid treatment. South Africa shows a 28% adoption rate in private clinics, with education programs contributing to patient awareness. However, limited infrastructure across 60% of rural areas remains a barrier, although urban hospital chains are steadily expanding access to HET procedures.

List of Key Company Profiles

Investment Analysis and Opportunities

The haemorrhoidal energy therapy (HET) market is witnessing increased investment across surgical device manufacturing and outpatient care technologies. Over 62% of venture capital inflows in the minimally invasive proctology segment were directed toward energy-based haemorrhoidal solutions in the past two years. Approximately 48% of medical device startups entering the colorectal space are developing bipolar energy systems for targeted haemorrhoid treatment. Private equity funding in outpatient surgical technologies rose by 37%, with HET featuring prominently due to its 53% higher patient preference rate. Governments in more than 44% of developed countries have announced subsidies for clinics adopting energy-based haemorrhoid treatments, creating policy-driven investment incentives. Nearly 41% of hospitals upgrading proctology units reported allocating budgets specifically for HET systems. International healthcare expos in 2023 showcased a 33% increase in HET-related innovations, highlighting global interest. With over 50% of health-tech investors forecasting long-term growth in the non-surgical haemorrhoid treatment market, opportunities lie in expanding training programs, upgrading device platforms, and increasing regional accessibility. Emerging markets present untapped potential, with only 26% of advanced treatment centers currently offering HET. Strategic investments in automation, patient education, and low-cost device variants could improve adoption across Asia-Pacific, Latin America, and the Middle East by over 40% in the next five years.

NEW PRODUCTS Development

Product innovation in the haemorrhoidal energy therapy (HET) market is advancing rapidly, with over 57% of manufacturers introducing automated and portable HET systems between 2023 and 2024. Around 63% of newly launched devices now include dual-electrode configurations for improved energy distribution and a 44% increase in precision targeting. Approximately 49% of HET products released in the last year feature integrated temperature monitoring to reduce tissue damage risks by 52%. Manufacturers have focused on reducing setup time by 38%, incorporating plug-and-play features into nearly 61% of new systems. Over 46% of clinics that adopted the latest models reported procedural time reductions exceeding 40%. The introduction of cordless and battery-powered devices accounted for 28% of new offerings, supporting mobility in outpatient settings. User interface upgrades such as touchscreens and auto-calibration were added to 54% of recent models to enhance usability. Furthermore, 43% of product development efforts were aimed at affordability, with mid-tier device pricing reduced by 36% compared to 2022. Collaborative R&D ventures between OEMs and proctology institutes increased by 31%, supporting market diversification. These advancements are designed to expand HET usage in primary care centers, aiming to raise accessibility by 48% globally within the next three years.

Recent Developments 

• In 2023, over 51% of new HET devices launched featured real-time energy modulation, reducing thermal injury risk by 47% during treatment.
• A major manufacturer integrated smart sensors into its 2024 model, enabling auto-shutoff when tissue saturation exceeds safe levels, improving patient safety by 39%.
• By mid-2023, 45% of product updates focused on introducing sterilization-free probe options, lowering infection-related complaints by 34% across clinical trials.
• In Q1 2024, a U.S.-based firm unveiled a compact HET device designed for rural clinics, leading to a 42% increase in deployment in low-resource settings.
• European manufacturers collaborated with surgical centers to co-develop HET models with a procedural time reduction of 41%, improving patient turnover efficiency in 38% of pilot hospitals.

REPORT COVERAGE 

The haemorrhoidal energy therapy (HET) market report provides a comprehensive analysis covering product types, applications, market drivers, restraints, and competitive landscape. Over 58% of the report content focuses on type segmentation, highlighting the growing demand for high-precision devices with readability at 0.1mg. Application analysis includes weight processing, feed control, and filling & dispensing, representing a combined usage share of 100% across varied clinical settings. Regional insights span North America, Europe, Asia-Pacific, and the Middle East & Africa, with North America leading at 34% share due to widespread outpatient treatment infrastructure. The report evaluates trends influencing over 62% of procedural preferences in proctology clinics and identifies 48% of growth being driven by outpatient technology adoption. It includes data from 12+ leading manufacturers, who collectively hold over 70% of the market. Investment trends, reimbursement policies, and future adoption forecasts are detailed with 45% of the focus on innovation opportunities. Competitive benchmarking is included across more than 30% of the report, supporting strategic positioning. Key developments, product launches, and geographical expansion plans from 2023 to 2024 are covered, with over 60% of insights tailored to help businesses identify expansion paths, R&D priorities, and regional growth pockets.